Kronox Lab Sciences IPO: 10 key risks investors should know before subscribing to the issue
₹130.15 crore.Vadodara-based Kronox is a manufacturer of speciality fine chemicals. Many sectors, including biotech, pharmaceutical formulations, active pharmaceutical components, metallurgy, agrochemicals, animal health, and scientific research and testing, employ its products for a variety of purposes.Also Read: Kronox Lab Sciences IPO: GMP, review, subscription status, other details.
Apply or not?It operates a Research, Development, and Testing (RDT) laboratory in Vadodara, Gujarat, in addition to three production plants. In addition, the business has purchased property in Gujarat's Dahej to build a new manufacturing facility.
It sells to over 20 countries, with the US, the UK, Mexico, Australia, and Egypt being among its top destinations.15% of the issue size has been allocated for non-institutional investors, 35% for retail investors, and half for eligible institutional purchasers. Investors may also place bids for up to 110 equity shares, with multiples of 110 equity shares thereafter.The only book-running lead manager is Pantomath Capital Advisors.
The company's equity shares are proposed to be listed on the BSE and the NSE.Also Read: Kronox Lab Sciences IPO fully booked within an hour of opening on strong retail, NII demand; check GMP, other detailsHere are some of the key risks listed by the company in its Red-Herring Prospectus (RHP):Also Read: Kronox Lab Sciences IPO opens on June 3; here's what GMP hints ahead of subscriptionAlso Read: Kronox Lab Sciences IPO to open on June 3; check GMP, price band, issue size, key dates, more.Disclaimer: The views and recommendations above are those of individual analysts, experts, and brokerage firms, not Mint. We advise investors to consult certified experts before making
. Read more on livemint.com
